Medical/Pharmaceuticals

ABILITY Diabetes Global enrolls thousandth patient: A Cardinal Milestone Achieved

TAMPA, Fla., Sept. 9, 2021 /PRNewswire/ -- ABILITY Diabetes Global  (Randomized Comparison ofAbluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellit...

2021-09-09 19:26 4054

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- PAQ Therapeutics ("PAQ"), a biotechnology company harnessing the power of autophagy to restore health and cure disease, and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced tha...

2021-09-09 19:20 3185

Proximie Partners with Teladoc Health to Connect Operating Rooms Globally

Proximie software to be integrated in Teladoc Health's Solo™ platform ecosystem for hospitals and health systems, enabling an integrated experience for surgeons BOSTON, Sept. 9, 2021 /PRNewswire/ -- Proximie, a health technology platform focused on digitizing operating and diagnostic rooms, today...

2021-09-09 19:00 3530

AIA Live Returns For 2021: Helping People Live Healthier, Longer, Better Lives

HONG KONG, Sept. 9, 2021 /PRNewswire/ -- AIA's Global Ambassador David Beckham talks "Tai Chi" and mental health as he joins fellow AIA health and wellness ambassadors, industry experts and leading influencers from acrossAsia for AIA Live 2021. The inaugural AIA Live 2020, which streamed on AIA'...

2021-09-09 18:46 2881

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:12 2868

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:06 3014

B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System

TOKYO, Sept. 9, 2021 /PRNewswire/ -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at its factory, for a compact proton cancer therapy system under development, and confirmed the generation of a magnetic field. That means a major ...

2021-09-09 15:00 1928

Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting

BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Ass...

2021-09-09 15:00 3297

Nanoform technology delivers successful results for Herantis CDNF drug candidate

HELSINKI, Sept. 9, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc ("Herantis"), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebr...

2021-09-09 14:04 2065

Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility

SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...

2021-09-09 11:40 4480

WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer

SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhi...

2021-09-09 08:26 7027

CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC WCLC 2021

SUZHOU, China, Sept. 9, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced that efficacy and safety data from a...

2021-09-09 08:00 4716

HaemaLogiX raises $10 million to advance multiple myeloma treatments

* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...

2021-09-09 05:00 2763

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met

SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of  pyrilutamide ("KX-8...

2021-09-08 22:13 4929

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

-- First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX–CoV2373 vaccine with Matrix-M™ adjuvant -- Phase 1/2 study will evaluate immunogenicity and safety GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated...

2021-09-08 20:30 6606

Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of brea...

2021-09-08 20:08 4890

The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare

Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...

2021-09-08 19:00 4300

HICOOL 2021 Global Entrepreneur Summit

BEIJING, Sept. 8, 2021 /PRNewswire/ -- HICOOL 2021 Global Entrepreneur Summit, a global event for entrepreneurs, will be held inBeijing on September 10-11, 2021, at the Beijing International Exhibition Center (New Venue) in Shunyi, Beijing, with the theme "Connect Startups Worldwide, Innovate Bei...

2021-09-08 16:30 2416

Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets Granted Drug Certificate

SHIJIAZHUANG, China, Sept. 8, 2021 /PRNewswire/ -- Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate byChina's National Medical Products Administration (NMPA). With the functions of reinforcing kidney, n...

2021-09-08 12:28 3328

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple ...

2021-09-08 11:04 3103
1 ... 620621622623624625626 ... 649